Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients

NCT02921789 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

67

Enrollment

INDUSTRY

Sponsor class

Conditions

Kidney Transplantation
Primary Focal Segmental Glomerulosclerosis (FSGS)

Interventions

DRUG: Bleselumab
DRUG: Basiliximab
DRUG: Mycophenolate Mofetil (MMF)
DRUG: Tacrolimus Capsules
DRUG: Methylprednisone
DRUG: Prednisone

Sponsor

Astellas Pharma Global Development, Inc.

Collaborators

[object Object]